VEGFA low ratio of VEGF165b/VEGFtotal

CI-VAR-00004985Explore in graph →CIViC 3323

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm2
VEGFA low ratio of VEGF165b/VEGFtotal	Bevacizumab	Predictive	B	Supports Sensitivity Response	5	rejected	EID9296 Tumor samples from the phase III trial of FOLFOX4 bevacizumab were assessed for VEGF165b and VEGFtotal by immunohistochemistry and scored relative to normal mucosal tissue. Low ratio of VEGF165b/VEG… (full text at CIViC) PMID 23104894 · Bates et al., 2012 · Open in CIViC	civic
VEGFA low ratio of VEGF165b/VEGFtotal	Bevacizumab	Predictive	B	Supports Sensitivity Response	4	submitted	EID9358 Tumor samples with low ratio of VEGF165b/VEGFtotal treated with bevacizumab compared to placebo showed a trend toward improved PFS (HR 0.49; 95% CI, 0.26 to 0.93). The trend was not significant with p… (full text at CIViC) PMID 23104894 · Bates et al., 2012 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.